NCT05611931Phase 3Active not recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-08Estimated

Enrollment · participants257Actual

Source updated2026-08-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-29 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~276 participants (planned)~~

+ After

257 participants (actual)

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Posted 2025-10-03 · 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Progression Free Survival (PFS) ~~Assessed by Investigator as~~ per RECIST v1.1

+ After

Measure: Investigator assessed Progression Free Survival (PFS) per RECIST v1.1

Planned enrollment increased by 56 participants

− Before

~~220 participants (planned)~~

+ After

276 participants (planned)

Primary completion date changed

− Before

~~31 Jan 2025~~

+ After

Aug 2026

Check registry source